Pharma Works – Tenil http://www.tenil.net/ Thu, 13 Jan 2022 11:15:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://www.tenil.net/wp-content/uploads/2021/05/tenil-icon-150x150.png Pharma Works – Tenil http://www.tenil.net/ 32 32 Clamshell Packaging Market to Reach US$19 Billion Revenue by 2032 https://www.tenil.net/clamshell-packaging-market-to-reach-us19-billion-revenue-by-2032/ Thu, 13 Jan 2022 11:15:00 +0000 https://www.tenil.net/clamshell-packaging-market-to-reach-us19-billion-revenue-by-2032/

global-pharma-blister-packaging-market-forecast-2022-2032

Blister packaging is the strongest type of packaging in the pharmaceutical industry as it helps to protect various pharmaceutical products from the factors

ROCKVILLE, MARYLAND, USA, Jan. 13, 2022 /EINPresswire.com/ — The pharmaceutical blister packaging market is expected to reach US$10.5 billion in 2022 and is expected to reach US$19 billion by 2032, with a CAGR of 6% from 2022-2032. Fact.MR – a market research and competitive intelligence provider, foresees moderate growth in the demand for the pharmaceutical blister packaging market.

The packaging industry is estimated to be around US$300 billion with the pharmaceutical packaging industry accounting for around 4% of the market share in 2022. Additionally, the blister packaging market is valued at 15 billion US dollars, in which 70% of the market share will be captured by the pharmaceutical blister packaging market. However, under the umbrella of the global pharmaceutical packaging industry, the pharmaceutical blister packaging market accounts for more than 85% of the market share and is valued at approximately US$9.8 billion in 2020.

Moreover, it also gives significant and actionable insights into Pharmaceutical Packaging Market competitive analysis which expands on the present market scenario and will be lucrative for the future Pharmaceutical Packaging Market demand.

Click here for sample report (including full TOC, table and figures): – https://www.factmr.com/connectus/sample?flag=S&rep_id=452

Key Segments Covered
type of product
valve
Card
Type of technology
Cold forming
Thermoforming
type of material
Polyethylene terephthalate (PET, PETE, PETG or polyester)
High Density Polyethylene (HDPE)
Polyvinyl chloride (PVC)
Low density polyethylene (LDPE)
Aluminum
Paper and Cardboard
Application
Tablets
capsules
Powders
Medical equipement

We leverage space-age digitization and industrial tools to provide our clients with actionable cutting-edge insights into the pharmaceutical packaging market.

A SWOT analysis has been carried out in the market study to study the strengths, weaknesses, opportunities and threats of each player on both a global and regional level.

Crucial insights into the Pharmaceutical Blister Packaging Market research report:

Underlying macro and micro-economic factors impacting the Pharmaceutical Blister Pack Sales Market.
Basic overview of Pharma Blisters Packaging including market definition, classification and applications.
Examination of each market player based on mergers and acquisitions, R&D projects and product launches.
Adoption trend and supply analysis of pharmaceutical blister packaging in various industries.
Important regions and countries providing lucrative opportunities for market players.

Need more information on the reporting methodology? Click here:-https://www.factmr.com/connectus/sample?flag=RM&rep_id=452

This report gives you access to critical data such as:

Pharmaceutical Blister Packaging Market Demand and Growth Drivers
Factors limiting the growth of the Pharmaceutical Packaging Market
Current Key Trends in the Pharmaceutical Blister Packaging Market
Pharmaceutical Blister Packaging Market Size and Pharmaceutical Blister Packaging Sales Projections for the coming years

Key Question Answered in the Pharmaceutical Packaging Market Survey Market Report by Fact.MR

Pharma Blisters Packaging Company & Brand Share Analysis: Analysis of company and brand share in the Pharma Blisters Packaging market reveals the market share captured by Tier 1, Tier 2 and Tier 2 players. 3
Pharmaceutical Blister Packaging Market Historical Volume Analysis: The industry analysis provides data and information on historical volume sales of Pharmaceutical Blister Packaging.
Manufacturing Trends Analysis: Vital insights on how market players are aligning their manufacturing strategies based on changing consumer sentiment
Pharmaceutical Blister Packaging Market Merger and Acquisition Activity: MR analysis also includes analysis of merger and acquisition activity. Manufacturers and stakeholders of the Pharmaceutical Thermoformed Packaging market will not only know about the recent mergers and acquisitions but also understand its impact on the competitive landscape and market share
Pharmaceutical Blister Packaging Market Demand by Country: The report forecasts the Pharmaceutical Blister Packaging demand by country, giving business leaders the insights needed to know the fast-growing, stable and mature markets

The report also presents key trends in the Pharmaceutical Packaging market and an in-depth analysis of how the projected growth factors will shape the Pharmaceutical Packaging market dynamics in the coming years of the forecast period.

The Pharma Blisters Packaging Market insights will enhance the impact on revenue for businesses across various industries by:

To provide a suitable framework for understanding the attractiveness quotient of various products/solutions/technologies in the Pharmaceutical Blister Packaging market
Guide stakeholders to identify key issues related to their consolidation strategies in the Global Pharmaceutical Packaging Market and propose solutions
Assess the impact of changing regulatory dynamics in regions where companies want to expand their footprint
Provides an understanding of disruptive technology trends to help companies make their transitions smoothly
Helping leading companies recalibrate their strategy before their competitors and peers
Offers an overview of promising synergies for the top players aiming to retain their leading position in the market and supply analysis of the Pharmaceutical Packaging Market.

The Pharmaceutical Blister Packaging demand market study includes the current market scenario on the global platform along with the sales development of the Pharmaceutical Blister Packaging over the forecast period.

To Obtain All-Inclusive Regional Landscape Information of Pharma Blisters Packaging Market, Shop Now:- https://www.factmr.com/checkout/452

Why has smart blister packaging sparked demand?

Smart blister packaging is one of the megatrends gaining momentum in the pharmaceutical packaging market. Companies are turning to smart blister packaging from traditional packaging. Intelligent blisters are developed to monitor the state of drugs during transport, in order to fight against medical counterfeiting.

Manufacturers are using state-of-the-art technology and integrating radio frequency identification (RFID) into blister packs, which simplifies the supply chain process by keeping track of the status and progress of pharmaceutical products in motion. RFID tags on the blister packs also help verify the contents of the pack using a digital code on the tape. This eliminates the need to break a tamper evident seal and also saves time. The emergence of smart packaging has streamlined the supply chain by reducing lead times through each node.

Check out Fact.MR’s comprehensive coverage of the chemicals and materials landscape

Liquid Polybutadiene Market, https://www.factmr.com/report/4143/liquid-polybutadiene-market

Polymer Seals Market – https://www.factmr.com/report/586/polymer-seals-market

Die Bonding Pastes Market – https://www.factmr.com/report/die-bonding-pastes-market

List of Key Companies Profiled in Pharmaceutical Blister Packaging Market are:

To provide decision makers with credible information about their competitive landscape, the Pharmaceutical Packaging Market industry research report includes a detailed analysis of the competitive landscape.

The competitive landscape analysis for the Pharmaceutical Packaging market includes detailed profiles of Tier 1, 2, and 3 players. The respective market share of Pharma Blisters Packaging manufacturers is provided so that business owners can understand the scenario of the market.

An assessment of the winning strategies of the pharmaceutical packaging market leading manufacturers is provided, along with recommendations on what is performing well in the pharmaceutical packaging market landscape.

Browse more reports by Fact.MR: -https://www.globenewswire.com/en/news-release/2018/03/09/1419691/0/en/Rigid-Non-Compartmental-Trays-to-Register- Highest-Growth-of-the-global-aluminum-foil-packaging-market-in-2017-2026.html

Contact:
USA Sales Office:
11140 Rockville Pike
Office 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com

The head office:
Unit number: AU-01-H (AU) gold tower,
Parcel number: JLT-PH1-I3A,
Jumeirah Lakes Tours,
Dubai, United Arab Emirates

Supriya Bhor
LEADING RESEARCH AND CONSULTANCY SERVICES
+91 9922699448
write to us here

]]>
Bob Nelsen and Anne Wojcicki join $ 20million funding round for longevity startup in hopes of slowing ovarian aging – Endpoints News https://www.tenil.net/bob-nelsen-and-anne-wojcicki-join-20million-funding-round-for-longevity-startup-in-hopes-of-slowing-ovarian-aging-endpoints-news/ Tue, 11 Jan 2022 15:39:00 +0000 https://www.tenil.net/bob-nelsen-and-anne-wojcicki-join-20million-funding-round-for-longevity-startup-in-hopes-of-slowing-ovarian-aging-endpoints-news/

After helping spawn some of the early anti-aging upstarts, Bob Nelsen found another new idea to love in the burgeoning space.

The CEO of ARCH is part of a union that is donating $ 20 million in Series A money to Gameto, a New York-based biotechnology company whose stated mission is to reprogram ovarian cells to slow the aging process. ovary – which is very “accelerated” compared to other organs, according to the company.

Other investors include 23andMe founder Anne Wojcicki, Future Ventures, Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures and Overwater Ventures.

“The ovaries age five times faster than other organs, resulting in infertility, early menopause and years of increased ill health for women,” CEO Dina Radenkovic said in a statement. “We want to change the narrative of women’s reproductive longevity and address the root causes of gender inequality in our society. “

Trained in the UK and US, Radenkovic was co-founder and CSO of a longevity clinic in London and spent the last year as a visiting scientist at the Buck Institute in California before joining Gameto in August. last.

Maryanna saenko

Building on initial research from the George Church lab, the company said its platform is built on three pillars: one to improve assisted fertility, another to kickstart drug discovery, and the last to “return the medical burden. of optional menopause ”.

Details are scarce, but in an interview with TechCrunch, Radenkovic noted that the company has started testing whether ovarian support cells can help eggs mature and reduce the number of IVF cycles.

The technology also has the potential to disrupt today’s treatment landscape, added Maryanna Saenko, co-founder of Future Ventures. Saenko described hormone replacement therapy as “blunt hammers, lacking in personalization.”

“The suffering caused by menopause is not a biological imperative,” she said, “and the many complications that accompany menopause, especially early menopause, can be avoided entirely.”

]]>
Caspofen Market 2022 – Strategic Assessment by Major Key Players https://www.tenil.net/caspofen-market-2022-strategic-assessment-by-major-key-players/ Sun, 09 Jan 2022 18:02:36 +0000 https://www.tenil.net/caspofen-market-2022-strategic-assessment-by-major-key-players/

New Jersey, United States, – Market Research Intellect has been analyzing the Caspofen technology and markets since 2018. Since then, through the analysis of company research, we have been very close to the latest market research and development.

In addition, Market Research Intellect works closely with many clients to help them better understand technology and the market environment and to develop innovation and commercialization strategies.

Market Research Intellect offers extensive expertise in analyzing the Caspofen market. We have been in this industry for 20 years and have closely followed the rise and / or fall, success and / or disappointment of many emerging technologies during this time.

This gives us a unique eye of experience when it comes to analyzing emerging technologies in electronic materials. This is very important as it helps to build a realistic market and technology roadmap that reflects the true potential of the technology based on its intrinsic characteristics and the true level of technology and business challenges it faces.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=419409

Further, the market revenue by region and country is provided in the Caspofenes report. The report’s authors also shed light on common business tactics adopted by players. The major players in the global bCaspofen market and their complete profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Caspofen market are mapped by the report. As a result of this report, key players in the global Caspofen Market will be able to make right decisions, and plan their strategies accordingly, to stay ahead of the game.

The competitive landscape is an essential aspect that any key player should be aware of. The report highlights the competitive scenario of the Global Caspofen Market to know the competition at the national and global level. The market experts also provided an overview of each major player in the global Caspofen market, taking into account key aspects such as business areas, production, and product portfolio. Further, the companies in the report are studied on the basis of key factors such as company size, market share, market growth, revenue, production volume, and profit.

The main players covered by the caspofen markets:

  • DSM Sinochem Pharma
  • JSN Chemicals Ltd.
  • Brightgene Bio-Medical Technology Co. Ltd
  • Jiangsu Shengdi Pharma
  • Suzhou Co Pharmaceutical Factory No.4

Caspofen Market Breakdown by Type:

Caspofen Market Split By Application:

  • 50 mg (base) / vial Injection product
  • 70 mg (base) / vial Injection product
  • Single dose vial injection product
  • Others

The Caspofen market report has been separated into distinct categories such as product type, application, end user, and region. Each segment is rated on the basis of CAGR, share and growth potential. In the regional analysis, the report highlights the potential region, which is expected to generate opportunities in the global Caspofen Market in the coming years. This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the Global Caspofenes Market and its growth potential in the coming years.

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=419409

Scope of Caspofen Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

Regional Market Analysis Caspofen can be represented as follows:

Each regional sector of Caspofen is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and to ensure you stay ahead of the competition.

Geographically, the global caspofen market has segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

Key questions answered in the report:

  • What is the growth potential of the caspofen markets?
  • Which product segment will take the lion’s share?
  • Which regional market will emerge as a precursor in the years to come?
  • Which application segment will grow at a sustained rate?
  • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
  • What are the main challenges that the global caspofen markets may face in the future?
  • Who are the leading companies in the global caspofen market?
  • What are the main trends that are positively impacting the growth of the market?
  • What are the growth strategies considered by the players to maintain their grip on the global caspofen market?

For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-caspofene-market-size-and-forecast/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Caspofen market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical caspofen distribution data from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intelligence

Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/

]]>
Better facilities for investors, Pinarayi Vijayan tells business leaders to invest in Kerala https://www.tenil.net/better-facilities-for-investors-pinarayi-vijayan-tells-business-leaders-to-invest-in-kerala/ Sat, 08 Jan 2022 00:51:29 +0000 https://www.tenil.net/better-facilities-for-investors-pinarayi-vijayan-tells-business-leaders-to-invest-in-kerala/

Speaking to Telangana business leaders at an Investment Road Show, Kerala Chief Minister Pinarayi Vijayan said the state will provide investors with facilities comparable to the best available in the country.

The Chief Minister stressed that the state is looking for strategic partnerships and we can assure that the state facilities are comparable to the best in the country.

The state is endowed with strengths superior to those found in other parts of the country, said the chief minister: “we are fortunate to have plentiful water, a clean and hygienic environment. . We can provide the most literate workforce in the country. country which is even comparable to several regions of developed countries.

He invited business leaders to share the state’s development aspirations and become a partner in our genuine and sincere quest to achieve inclusive socio-economic development.

“Kerala aims to become the best investment-friendly state in the country by attracting more investors for industries that do not undermine environmental sustainability. The government would achieve this goal with determination and care, ”said the Chief Minister.

John Brittas, MP, said many people are spreading disinformation about Kerala, but the point is that there is a good environment for investment in the state.

Alla Ayodhya Rami Reddy, MP, praised the development work in Kerala and its great achievements under the leadership of the Chief Minister.

Investment opportunities in Kerala were presented during the meeting. State investment opportunities in biotechnology, information technology, pharmacy and other emerging sectors were presented to entrepreneurs.

Legislative reforms are initiated by the State, digital transformation, simplification of procedures and industrial infrastructure were also explained. Industry hailed Kerala’s investor-friendly atmosphere.

(With contributions from agencies)

To subscribe to Mint newsletters

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our app now !!

]]>
Elizabeth Holmes, fallen Silicon Valley star, convicted of defrauding investors https://www.tenil.net/elizabeth-holmes-fallen-silicon-valley-star-convicted-of-defrauding-investors/ Tue, 04 Jan 2022 02:41:33 +0000 https://www.tenil.net/elizabeth-holmes-fallen-silicon-valley-star-convicted-of-defrauding-investors/

Fallen US biotech star Elizabeth Holmes was convicted on Monday of defrauding investors in her blood-testing startup Theranos in a high-profile case seen as an indictment against Silicon Valley culture.

Holmes is a rare example of a tech executive brought in to deal with a burning business, in an industry littered with the carcasses of losing companies that once promised untold wealth.

His case shed light on the blurry line between the bustle that characterizes the industry and outright criminal dishonesty.

Jurors took seven days of deliberation to render their verdict, finding her guilty on four counts of tricking investors into pouring money into what she claimed was a revolutionary testing system.

But the panel – which had listened to weeks of sometimes complex evidence – also acquitted her of four counts and was unable to rule on three others.

The 37-year-old now faces 20 years in prison for each conviction. She remains at large ahead of another bail hearing next week. No date has been set for sentencing.

She made no comment when she left court when asked if she intended to appeal.

Holmes was committed to revolutionizing health diagnostics with self-service machines capable of performing a series of tests on a few drops of blood, a vision that attracted high-profile donors and made her a billionaire at the age of 30.

She was hailed as the next tech visionary on magazine covers and raised mountains of investor money, but it all fell apart after The Wall Street Journal revealed the machines were not performing as promised .

Prosecutors spent 11 weeks presenting more than two dozen witnesses, as they painstakingly laid out their argument that Holmes knew his technology was insufficient and had deliberately misled investors and patients.

She personally put the logos of pharmaceutical giants Pfizer and Schering-Plow on Theranos reports praising the company’s blood testing technology, which were then shared with investors.

This was done without the clearances from the companies and was a key part of the prosecution’s argument that it deliberately attempted to inflate Theranos’ credibility in order to gain support.

– ‘Pretend until you do’ –

Although high-profile Theranos investors like Rupert Murdoch and Henry Kissinger were on the witness list, the biggest backer to take a stand was former Pentagon chief Jim Mattis.

The defense called only one important witness, Holmes herself, as they claimed that the fallen entrepreneur genuinely believed in Theranos’ vision, invested heavily in her success, and simply failed.

Holmes also sought to place some of the blame on Ramesh “Sunny” Balwani, a boyfriend nearly two decades her senior whom she brought in to help run her business.

She fought back tears as she told jurors that Balwani had disparaged and sexually imposed himself on her when he was angry – accusations he firmly denied.

He is to be tried separately for his role in the company’s operations and has pleaded not guilty.

Beyond the reams of company documents, very detailed technical questions and the sometimes moving testimony of Holmes, was the question of the very nature of Silicon Valley.

One of the most repeated clichés in the startup world is “pretend until you do,” where ambitious entrepreneurs with an idea that almost works convinces people to invest huge sums of money in the hope that it will work. ‘one day that will be the case.

It is extremely rare that the founders of failed Silicon Valley companies – of whom there are many – are prosecuted for fraud over unfulfilled promises and unreimbursed investments.

Some tech figures, like former Reddit chief Ellen Pao, said sexism may have been a factor in the lawsuits, but others argued Holmes went too far in trying to support his gradually dissolving vision.

After the 2015 Wall Street Journal report questioning whether Theranos’ machines were performing as promised – and ultimately bringing the company down – Holmes went on the offensive in the media.

“First they think you’re crazy, then they fight you, then all of a sudden you change the world,” said in a TV interview.

This story was posted from an agency feed with no text editing. Only the title has been changed.

To subscribe to Mint newsletters

* Enter a valid email address

* Thank you for subscribing to our newsletter.

Never miss a story! Stay connected and informed with Mint. Download our app now !!

]]>
New year brings more canceled flights for air travelers https://www.tenil.net/new-year-brings-more-canceled-flights-for-air-travelers/ Sun, 02 Jan 2022 01:09:55 +0000 https://www.tenil.net/new-year-brings-more-canceled-flights-for-air-travelers/

DHAKA: The world’s first generic version of Pfizer’s new COVID-19 treatment was already available in pharmacies in Bangladesh on Saturday, two days after the country’s drug regulator cleared its emergency use.

Pfizer’s new drug, Paxlovid, is a combined oral therapy for people with mild to moderate symptoms who are at high risk of developing severe COVID-19. In a clinical trial, a five-day course of treatment reduced the risk of hospitalization and death from coronavirus by 89%. The United States Food and Drug Administration cleared it for emergency use on December 22.

Two large Bangladeshi pharmaceutical companies, Beximco Pharma and Eskayef, started work on the generic version of the drug last year, after Pfizer’s first trials showed its high potential to treat COVID-19.

On Thursday, the country’s Directorate General of Medicines Administration granted emergency use authorization for the two drugs. The treatment of Beximco Pharma entered pharmacies in the capital under the name of Bexovid, while that of Eskayef under the name of Paxovir.

“As soon as we observed the success of Pfizer’s drug combination for the treatment of COVID-19 in early 2021, we began the product development process,” Beximco COO told Arab News. , Rabbur Reza.

“We started supplying it to the main pharmacies in Dhaka on Thursday evening. Gradually, we will start supplying pharmacies across the country. ”

Paxovir will need a few more days to enter the market, said Eskayef’s marketing director, Dr Mohammad Mujahidul Islam.

“It’s not a drug that is commonly used. Thus, we will only deliver it to strategic points such as designated COVID-19 hospitals and some selected pharmacies across the country. It will take a week to reach the market, ”he told Arab News.

Pfizer’s treatment is protected by patents, but countries like Bangladesh, which are classified by the UN as least developed countries, are not bound by them and may make their own generic versions of more affordable drugs.

As Pfizer has announced, the US federal government will purchase 10 million courses of Paxlovid for $ 5.3 billion, bringing the cost of the treatment to $ 530. Its generic version available in Bangladesh is much cheaper.

A five-day course of Bexovid from Beximco costs around $ 190 at drugstores in Dhaka. Eskayef’s Paxovir will cost around $ 176, according to Islam. “We will try to reduce the price gradually,” he said.

In some pharmacies in Dhaka it immediately sold out.

Sohag Babu, a salesperson at Lazz Pharma, one of the capital’s largest drugstore chains, said the store sold its supplies as soon as they received them: “It just hit the market ago. two days. We immediately received inquiries from customers.

While Bangladesh is not currently experiencing a wave of COVID-19 infections, a new viral wave is expected to hit the country in the coming months. The availability of the new drug gives hope that the country would be able to save more people from the disease.

“If we are faced with an increase in the rate of infections, which is a fear for the months of next March-April, we will be able to manage the situation effectively”, said Professor Dr Benazir Ahmed, former director of the Center. for Disease Control, told Arab News. “This will reduce the number of hospitalizations and the stay of patients in hospitals.”

But the drugs, although cheaper than the original treatment, may still be out of the reach of ordinary Bangladeshis.

Ahmed said the drug regulator and government could play a role here by making them available to the poor as well.

“Our DGDA can also take into account the pricing issues of new COVID-19 drugs so that they also remain affordable for the poor,” he said.

“To ease the burden on the poor, the government can source these drugs from manufacturers and deliver them to designated COVID-19 hospitals. ”

]]>
Top Companies 2021 Pharmaceuticals and Cetirizine OTC Market Size Analysis https://www.tenil.net/top-companies-2021-pharmaceuticals-and-cetirizine-otc-market-size-analysis/ Fri, 31 Dec 2021 07:37:52 +0000 https://www.tenil.net/top-companies-2021-pharmaceuticals-and-cetirizine-otc-market-size-analysis/

New Jersey, United States, – Market Research Intellect has been analyzing the technology and markets for Pharma and Cetirizine OTC since 2018. Since then, through the research analysis of companies, we have been very close to the latest research and market developments.

In addition, Market Research Intellect works closely with many clients to help them better understand technology and the market environment and to develop innovation and commercialization strategies.

Market Research Intellect offers extensive expertise in the analysis of the OTC Pharmaceutical and Cetirizine market. We have been in this industry for 20 years and have closely followed the rise and / or fall, success and / or disappointment of many emerging technologies during this time.

This gives us a unique eye of experience when it comes to analyzing emerging technologies in electronic materials. This is very important as it helps to build a realistic market and technology roadmap that reflects the true potential of the technology based on its intrinsic characteristics and the true level of technology and business challenges it faces.

Get | Download a sample copy with table of contents, graphics and list of [email protected] https://www.marketresearchintellect.com/download-sample/?rid=241124

Further, the market revenue by region and country is provided in the OTC Pharma and Cetirizine report. The report’s authors also shed light on common business tactics adopted by players. The major players in the global bPharma and Cetirizine OTC market and their complete profiles are included in the report. Additionally, investment opportunities, recommendations, and current trends in the global Pharma and Cetirizine OTC market are mapped by the report. As a result of this report, major players in the global OTC Pharma and Cetirizine Market will be able to make right decisions and plan their strategies accordingly to stay ahead of the game.

The competitive landscape is an essential aspect that any key player should be aware of. The report highlights the competitive scenario of the Global Pharma and Cetirizine OTC Market to know the competition at national and global level. The market experts also provided an overview of each major player in the global Pharma and Cetirizine OTC market, taking into account key aspects such as business areas, production, and product portfolio. Further, the companies in the report are studied on the basis of key factors such as company size, market share, market growth, revenue, production volume, and profit.

The main players covered by the Pharma and Cetirizine OTC markets:

  • UCB Pharma
  • Pfizer
  • NOT A WORD
  • Mylan
  • Suits you
  • HUAPONT pharmacy
  • Hunan Jiudian Pharm
  • Sun Pharma
  • Lunan pharmacy
  • Jubilant life sciences
  • Amneal
  • HAILISHENG

Distribution of the pharmaceutical and cetirizine OTC market by type:

Pharma and Cetirizine OTC market breakdown by application:

  • Hospital
  • Clinical
  • Pharmacy
  • Other

The Pharma and Cetirizine OTC market report has been separated into distinct categories such as product type, application, end user, and region. Each segment is rated on the basis of CAGR, share and growth potential. In the regional analysis, the report highlights the potential region, which is expected to generate opportunities in the global OTC Pharmaceuticals and Cetirizine Market in the coming years. This segmental analysis will surely prove to be a useful tool for the readers, stakeholders and market players to get a complete picture of the global Pharma and Cetirizine OTC Market and its growth potential in the coming years.

Get | Discount on purchasing this report @ https://www.marketresearchintellect.com/ask-for-discount/?rid=241124

Scope of Over-the-Counter Pharmaceuticals and Cetirizine Market Report

Report attribute Details
Market size available for years 2021 – 2028
Reference year considered 2021
Historical data 2015 – 2019
Forecast period 2021 – 2028
Quantitative units Revenue in millions of USD and CAGR from 2021 to 2027
Covered segments Types, applications, end users, etc.
Cover of the report Revenue forecast, company ranking, competitive landscape, growth factors and trends
Regional scope North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Scope of customization Free customization of reports (equivalent to 8 working days for analysts) with purchase. Add or change the scope of country, region and segment.
Price and purchase options Take advantage of custom shopping options to meet your exact research needs. Explore purchasing options

Regional Pharma and Cetirizine OTC Market Analysis can be represented as follows:

Each regional Pharma and Cetirizine OTC sector is carefully studied to understand its current and future growth scenarios. It helps the players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and to ensure you stay ahead of the competition.

Based on Geography, Global Pharma and Cetirizine OTC Market has segmented as follows:

    • North America includes the United States, Canada and Mexico
    • Europe includes Germany, France, UK, Italy, Spain
    • South America includes Colombia, Argentina, Nigeria and Chile
    • Asia-Pacific includes Japan, China, Korea, India, Saudi Arabia and Southeast Asia

Key questions answered in the report:

  • What is the growth potential of the Pharma and Cetirizine OTC markets?
  • Which product segment will take the lion’s share?
  • Which regional market will emerge as a precursor in the years to come?
  • Which application segment will grow at a sustained rate?
  • What are the growth opportunities that could emerge in the lock washer industry in the years to come?
  • What are the main challenges that the global Pharma and Cetirizine OTC markets could face in the future?
  • Who are the leading companies in the global Pharma and Cetirizine OTC market?
  • What are the main trends that are positively impacting the growth of the market?
  • What are the growth strategies envisaged by the players to maintain their hold on the global Pharma and Cetirizine OTC market?

For more information or a query or a personalization before purchasing, visit @ https://www.marketresearchintellect.com/product/global-pharma-and-cetirizine-otc-market-size-and-forecast/

Visualize OTC Pharmaceutical and Cetirizine Market Using Verified Market Intelligence: –

Verified Market Intelligence is our BI platform for telling the story of this market. VMI provides in-depth predictive trends and accurate insight into over 20,000 emerging and niche markets to help you make key revenue impact decisions for a bright future. VMI provides a comprehensive overview and global competitive landscape by regions, countries and segments, as well as as key players in your market. Present your market reports and findings with built-in presentation capabilities, delivering over 70% of time and resources to investors, sales and marketing, R&D and product development. VMI supports data delivery in interactive Excel and PDF formats and provides over 15 key market indicators for your market.

Visualize the Pharma and Cetirizine OTC market using VMI @ https: //www.marketresearchintellect.com/mri-intelligence/

The study thoroughly explores the profiles of the major market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants when designing their business strategies. This report covers the production, revenue, market share and growth rate of the Pharma and Cetirizine OTC market for each key company, and covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Historical breakdown data of Pharma and Cetirizine OTC from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intelligence

Market Research Intellect provides syndicated and personalized research reports to clients from various industries and organizations in addition to the goal of providing personalized and in-depth research studies. range of industries, including energy, technology, manufacturing and construction, chemicals and materials, food and beverage. Etc. Our research studies help our clients make more data-driven decisions, admit push predictions, grossly capitalize on opportunities, and maximize efficiency by acting as their criminal belt to adopt accurate mention and essential without compromise. clients, we have provided expertly-behaved affirmation research facilities to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.

Contact us:
Mr. Edwyne Fernandes
United States: +1 (650) -781-480
UK: +44 (753) -715-0008
APAC: +61 (488) -85-9400
US Toll Free: +1 (800) -782-1768

Website: –https://www.marketresearchintellect.com/

]]>
What will applied AI look like in 2022? https://www.tenil.net/what-will-applied-ai-look-like-in-2022/ Wed, 29 Dec 2021 22:21:38 +0000 https://www.tenil.net/what-will-applied-ai-look-like-in-2022/

Hear from CIOs, CTOs, and other senior executives and leaders on data and AI strategies at the Future of Work Summit on January 12, 2022. Learn more


AI adoption has exploded over the past 18 months. Besides Joe McKendrick, who wrote the seminal article on HBR, professionals working on AI would readily attest to this statement. Google search also appears to be in this not-so-secret area: When asked “Adopting AI,” its autocomplete gushes “have skyrocketed in the past 18 months.”

The anecdotal evidence and the investigations that we are aware of seem to point in the same direction. Example: The AI ​​Adoption in the Enterprise 2021 survey by O’Reilly, conducted in early 2021, received three times as many responses as in 2020, and corporate culture is no longer the main obstacle to adoption.

In other words, more and more people are working with AI, it is now taken seriously and maturity is increasing. It’s good news. This means AI is no longer a game researchers play – it is becoming applied, taking center stage for Microsoft and Amazon and beyond.

The following examines the pillars that we hope Applied AI will build on in 2022.

AI chips

Typically, when discussing AI, people think of models and data – and for good reason. These are the parts over which most practitioners believe they can exercise some control, while the material remains mostly invisible and its capabilities considered fixed. but is this the case?

AI chips, a new generation of hardware designed to optimally perform AI-related workloads, are experiencing explosive growth and innovation. Cloud mainstays like Google and Amazon are building new AI chips for their data centers – TPU and Trainium, respectively. Nvidia has dominated this market and built an empire around its hardware and software ecosystem.

Intel is looking to catch up, whether through acquisitions or its own R&D. Arm’s status remains somewhat unclear, with the announced acquisition by Nvidia undergoing regulatory review. Additionally, we have a slew of new players at different stages of their adoption journey, some of whom – like Graphcore and SambaNova – have already achieved unicorn status.

What this means for Applied AI is that choosing where to run AI workloads no longer simply means choosing between Intel processors and Nvidia GPUs. There are now many parameters to consider, and this development is not only important for machine learning engineers, but also for AI practitioners and users. AI workloads run more economically and efficiently mean there will be more resources to be used elsewhere with a faster time to market.

MLOps and data centricity

Selecting the hardware on which to run AI workloads can be seen as part of the end-to-end process of developing and deploying AI models, called MLOps – the art and science of putting it together. machine learning in production. To make the connection with AI chips, standards and projects like ONNX and Apache TVM can help bridge the gap and ease the tedious process of deploying machine learning models to various targets.

In 2021, with lessons learned from operationalizing AI, the focus is now on shiny new models towards perhaps more mundane, but practical, aspects such as data quality and pipeline management. data, all of which are important parts of MLOps. Like any discipline, MLOps sees many products on the market, each focusing on different facets.

Some products are more data driven, others are data pipelines, and some cover both. Some products monitor and observe such things as model inputs and outputs, drift, loss, precision and accuracy of data recall. Others are doing similar, but different, things around data pipelines.

Data-centric products meet the needs of data scientists and data scientists, and perhaps machine learning engineers and data analysts as well. Data pipeline-centric products are geared more towards DataOps engineers.

In 2021, people tried naming various MLOps-related phenomena, slicing and slicing the MLOps domain, applying data version control and continuous machine learning, and performing the equivalent. test-driven development for data, among others.

What we see as the most profound change, however, is the focus on so-called data-centric AI. Prominent thought leaders and AI practitioners such as Andrew Ng and Chris Ré have discussed this notion, which is surprisingly simple in its essence.

We have now reached a point where machine learning models are sufficiently developed and work well in practice. So much so, in fact, that there is no point in focusing efforts on developing new models from scratch or tuning to perfection. According to the data-centric view, what AI practitioners should instead do is focus on their data: cleaning, refining, validating and enriching data can go a long way in improving the results of AI projects. .

Large linguistic models, multimodal models and hybrid AI

Large Linguistic Models (LLMs) may not be the first thing that comes to mind when discussing applied AI. However, knowledgeable people believe that LLMs can internalize basic forms of language, be it biology, chemistry, or human language, and we are on the verge of seeing unusual applications of LLMs develop.

To substantiate these claims, it should be mentioned that we are already seeing some kind of ecosystem building around LLMs, primarily the commercially available GPT-3 API by OpenAI in collaboration with Microsoft. This ecosystem consists primarily of companies offering copywriting services such as marketing copy, email, and LinkedIn posts. They may not have set the market on fire yet, but this is just the start.

We believe that LLMs will experience increased adoption and lead to innovative products in 2022 in several ways: through more customization options of LLMs like GPT-3; through more options for creating LLMs, such as Nvidia’s NeMo Megatron; and through LLM as a service offerings, such as SambaNova.

As VentureBeat’s Kyle Wiggers noted in a recent article, multimodal models are quickly becoming a reality. This year, OpenAI released DALL-E and CLIP, two multimodal models which, according to research labs, are “a step towards systems with [a] better understanding of the world. Based on LLMs, one can reasonably expect to see commercial applications of multimodal models in 2022.

Another important direction is in hybrid AI, which is to infuse knowledge into machine learning. Executives such as Gadi Singer from Intel, Mike Dillinger from LinkedIn, and Frank van Harmelen from the Hybrid Intelligence Center all emphasize the importance of organizing knowledge in the form of knowledge graphs for the future of AI. It remains to be seen whether hybrid AI will produce applied AI applications in 2022.

Applied AI in Healthcare and Manufacturing

Let’s end with something more entrenched: promising areas for applied AI in 2022. O’Reilly’s adoption of AI in the Enterprise 2021 survey cites technology and financial services as the two leading areas. adoption of AI. This is hardly surprising, given the tech industry’s drive to “eat its own dog food” and the financial industry’s drive to gain every inch of competitive advantage possible by using its deep pockets.

But what is happening beyond these two industries? O’Reilly’s survey cites healthcare as the third area of ​​AI adoption, which is consistent with our own experience. As State of AI authors Nathan Benaich and Ian Hogarth noted in 2020, biology and healthcare is experiencing its AI moment. This wave of adoption was already underway, and the advent of COVID-19 has further accelerated it.

“The incumbent pharmaceutical industry is very motivated by an a priori hypothesis, saying, for example: ‘I think this gene is responsible for this disease, let’s go after it and find out if it’s true’. Then there are the more software-oriented people who are in this new era of pharma. They mainly look at large-scale experiments and ask a lot of questions at the same time. Impartially, they let the data draw the map of what they should be focusing on, ”said Benaich, summing up the AI-driven approach.

The only way to validate whether the new age pharmaceutical approach is working is whether it can generate drug candidates that are actually clinically useful, and ultimately get those drugs approved, Benaich added. Among these “new age pharma” companies, Recursion Pharmaceuticals went public in April 2021 and Exscientia filed for an IPO in September 2021. They both have assets generated from their market-based approach. machine learning that are actually used in the clinic.

As for manufacturing, there are several reasons why we choose to highlight it among the many areas lagging behind in AI adoption. First, it suffers from a workforce shortage that AI can help alleviate. According to a study published by Deloitte and The Manufacturing Institute, up to 2.1 million manufacturing jobs may go unfilled by 2030. AI solutions that perform tasks such as automated physical inspections products fall into this category.

Second, the nature of industrial applications requires combining sections of data with the physical world in a very precise manner. This, some people have noted, lends itself well to hybrid AI approaches.

And last but not least, the hard data. According to a 2021 survey by The Manufacturer, 65% of manufacturing leaders are working to drive AI. Warehouse implementation alone is expected to achieve a compound annual growth rate of 57.2% over the next five years.

VentureBeat

VentureBeat’s mission is to be a digital public place for technical decision-makers to learn about transformative technology and conduct transactions. Our site provides essential information on data technologies and strategies to guide you in managing your organizations. We invite you to become a member of our community, to access:

  • up-to-date information on the topics that interest you
  • our newsletters
  • Closed thought leader content and discounted access to our popular events, such as Transform 2021: Learn more
  • networking features, and more

Become a member

]]> Central government panel recommends EUA for Covovax, Corbevax, Molnupiravir: reports https://www.tenil.net/central-government-panel-recommends-eua-for-covovax-corbevax-molnupiravir-reports/ Tue, 28 Dec 2021 02:31:26 +0000 https://www.tenil.net/central-government-panel-recommends-eua-for-covovax-corbevax-molnupiravir-reports/

A central government panel from the Central Medicines Authority has recommended granting emergency use authorization (EUA) for the Serum Institute of India’s Covovax COVID-19 vaccine and the E Corbevax biologic vaccine, reported the PTI news agency. The Central Drugs Standard Control Organization (CDSCO) COVID-19 Subject Matter Expert Committee (SEC) also recommended on Monday that approval be granted to manufacture and market the anti-COVID pill Molnupiravir for use in Emergency restricted for the treatment of adult patients with 93 percent SpO2 who are at high risk of disease progression, including hospitalization or death, under certain conditions. All recommendations have been sent to the Drugs Controller General of India (DCGI) for final approval.

Covovax is a vaccine subunit developed by Novavax and the Coalition for Epidemic Preparedness Innovations (CEPI). It requires two doses and is stable at refrigerated temperatures of 2-8 ° C. The vaccine uses a new platform and is produced by creating a modified baculovirus containing a gene for a modified SARS-CoV-2 spike protein. The vaccine is already approved in Indonesia and the Philippines. The NOVOVAX vaccine on which COVOVAX is based was shown to be 89.7% effective after two doses and had “high efficacy” against variant B.1.1.7.

Biological E’s coronavirus vaccine, Corbevax, is an RBD protein subunit vaccine and is currently in Phase 2/3 clinical trials in adults. The Phase 3 trials are going to be a study compared to already licensed vaccines, although the study in children is not a comparative study. Biological E Ltd previously said it had reached an agreement with Janssen Pharmaceutica NV, part of pharmaceutical major Johnson & Johnson, for the creation and improvement of production capacities to manufacture the latter’s COVID-19 vaccine.

Molnupiravir works by blocking the ability of the virus to copy its genetic code and to replicate itself. If approved, it would be the first oral antiviral drug for COVID-19. All other available treatment options require an infusion or injection given in hospitals or clinics. A pill that can be taken at home could be a game-changer in the fight against the pandemic.

– Agency contributions

]]>
NIPER 2022 recruitment: notification for teaching and non-teaching positions on niperraebareli.edu.in https://www.tenil.net/niper-2022-recruitment-notification-for-teaching-and-non-teaching-positions-on-niperraebareli-edu-in/ Sun, 26 Dec 2021 10:57:04 +0000 https://www.tenil.net/niper-2022-recruitment-notification-for-teaching-and-non-teaching-positions-on-niperraebareli-edu-in/

NIPER Raebareli 2022 recruitment: The National Institute of Pharmaceutical Education and Research (NIPER), Raebareli issued the recruitment notification to hire eligible candidates for various teaching and non-teaching positions. Eligible and interested candidates can apply for the various teaching and non-teaching positions through the official NIPER website at niperraebareli.edu.in. The online application form started from December 24. The deadline to apply for the positions is until January 31, 2022.Also read – CGWB 2022 recruitment: apply for 24 positions before January 18 | Check eligibility, age limit, other details

Important dates to remember Also Read – Indian Coast Guard Recruitment 2021: Admission Card for Deputy Commander Post to be Posted December 28 at joinindiancoastguard.gov.in

Application deadline: January 31, 2022.
Deadline for receipt of a hard copy of the online application file: February 07, 2022. Also Read – SBI SCO 2022 Recruitment: Vacancies Notified for 7 Specialized Executive Officer Positions, Apply Online at sbi.co.in

Details of the vacant position

Name of positions and number of vacant positions

  • Teacher (Medicinal Chemistry): 01
  • Teacher (Pharmaceuticals): 01
  • Professor of Pharmacology & Toxicology: 01
  • Library and Information Officer: 01
  • Estate and security agent: 01
  • Doctor: 01
  • Public Relations Office: 01
  • Supervisor of guest house and inn: 01
  • Junior Hindi Translator: 01
  • Receptionist & Telephone operator: 01

Eligibility criteria

Professor (Medicinal Chemistry): Ph.D., in Pharmaceutical Sciences / Pharmaceutical Chemistry / Medicinal Chemistry / Chemistry of Natural Products with first class or grade equivalent to the previous diploma (M.Pharm / MS / M.Sc.) In Pharmaceutical Chemistry / Medicinal Chemistry / Chemistry / Organic Chemistry / Chemistry of natural products with a very good academic record and at least 10 years of teaching / research / industry experience with high quality published work, a well recognized and established reputation for bringing a remarkable seminal contribution to knowledge in the above areas.

Professor (Pharmaceuticals): Doctorate in Pharmaceutical Sciences with first class or degree equivalent to the previous diploma (M.Pharm / MS) in pharmacy / pharmaceutical technology (formulations) / industrial pharmacy with a very good academic record and at least 10 years of teaching / Research / Industrial experience with a good track record of publications (in SCI journals) / Patents in the fields mentioned above

Professor of Pharmacology & Toxicology: Doctorate in Pharmaceutical Sciences with first class or degree equivalent to the previous diploma (M.Pharma / MS / M.Tech / M.Sc.) In pharmacology and toxicology, regulatory toxicology, biotechnology / medical biotechnology / biomedical sciences with a very good academic record throughout and at least 10 years of teaching / research / industry experience with high quality published work, well known and known to have made a remarkable seminal contribution to knowledge in the pharmaceutical and related fields.

Library and Information Officer-Diploma in Library Science or Library and Information Science from a recognized university / institute

Estate and security agent-Bachelor’s degree in any discipline from a recognized university / institute.

How to register

Eligible candidates can apply for the various positions through the prescribed application format no later than January 31, 2022. Applicants are advised to consult the recruitment notification to learn more about the eligibility criteria, age limit and other details.

Click here: Detailed recruitment notification NIPER Raebareli

]]>